Recent Scientific Developments in Metastatic Prostate Cancer

Recent Scientific Developments in Metastatic Prostate Cancer

In recent years, the treatment landscape of advanced prostate cancer has radically changed [...]

Bibliographic Details
Main Author:	Isabel Heidegger
Format:	Article
Language:	English
Published:	MDPI AG 2020-11-01
Series:	Cancers
Subjects:	metastatic hormone-sensitive prostate cancer metastatic castration-resistant prostate cancer personalized therapy biomarker
Online Access:	https://www.mdpi.com/2072-6694/12/11/3280

Similar Items

Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer
by: Carlo Cattrini, et al.
Published: (2021-09-01)

NEW TREATMENT STANDARD FOR PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
by: B. Ya. Alekseev
Published: (2018-10-01)

Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations
by: Castellan P, et al.
Published: (2018-12-01)

Real-world experience with abiraterone in metastatic castration-resistant prostate cancer
by: Yasar Ahmed, et al.
Published: (2017-01-01)

Prediction for survival following docetaxel-based chemotherapy in Taiwanese men with castration-resistant metastatic prostate cancer
by: Kai-Fu Yang, et al.
Published: (2015-12-01)

Predictors for progression of metastatic prostate cancer to castration-resistant prostate cancer in Indians
by: Sanjoy Kumar Sureka, et al.
Published: (2016-01-01)

Role of chemotherapy in prostate cancer
by: Rita Nader, et al.
Published: (2018-01-01)

Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations
by: Patel SA, et al.
Published: (2017-08-01)

miRNAs as Therapeutic Tools and Biomarkers for Prostate Cancer
by: Noemi Arrighetti, et al.
Published: (2021-03-01)

New possibilities of combined antiandrogen therapy in patients with metastatic hormone-sensitive prostate cancer
by: B. Ya. Alekseev
Published: (2019-10-01)

Long-term complete remission with ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients
by: Luc Cabel, et al.
Published: (2017-04-01)

Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer
by: Edoardo Francini, et al.
Published: (2021-08-01)

POSSIBILITIES OF RADIUM-223 APPLICATION IN THERAPY OF PROSTATE GLAND CANCER
by: A. A. GRITSKEVICH, et al.
Published: (2017-06-01)

The National Registry of treatment regimens in patients with metastatic castration-resistant prostate cancer in the Russian Federation
by: O. B. Karyakin, et al.
Published: (2019-10-01)

Validation of Cell-Free RNA and Circulating Tumor Cells for Molecular Marker Analysis in Metastatic Prostate Cancer
by: Michael Ladurner, et al.
Published: (2021-08-01)

An exploratory first‐in‐man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2‐ and 1‐week interval in patients with metastatic castration resistant prostate cancer
by: Josephina P. M. Vrouwe, et al.
Published: (2021-10-01)

The prognostic value of tumor PD-L1 status in patients with metastatic prostate cancer
by: V. B. Matveev, et al.
Published: (2019-04-01)

Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience
by: Yang Liu, et al.
Published: (2021-01-01)

Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies
by: Mike Wenzel, et al.
Published: (2021-04-01)

Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
by: Dhruv Bansal, et al.
Published: (2021-01-01)

The new approaches to the treatment of castration- resistant prostate cancer: PARP inhibitors
by: А. А. Gritskevich, et al.
Published: (2021-06-01)

Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel
by: Zist Andrej, et al.
Published: (2015-12-01)

Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer
by: Vincenzo Di Nunno, et al.
Published: (2018-09-01)

Immune Checkpoints, Inhibitors and Radionuclides in Prostate Cancer: Promising Combinatorial Therapy Approach
by: Mankgopo M. Kgatle, et al.
Published: (2021-04-01)

Efficacy and Prognostic Factors of Docetaxel Rechallenge on Metastatic Castration-resistant Prostate Cancer Patients
by: DUAN Liqun, et al.
Published: (2019-09-01)

Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
by: Rebeca Lozano, et al.
Published: (2021-05-01)

Ureteral metastasis from locally invasive, castrate-resistant prostate cancer: a case report
by: Zachary C. Janatpour, et al.
Published: (2021-11-01)

Impact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives
by: Luo J, et al.
Published: (2016-11-01)

Current approaches to selection of the 1st line therapy in patients with metastatic hormone-sensitive prostate cancer
by: B. Ya. Alekseev, et al.
Published: (2018-01-01)

A Systematic Review and Meta-Analysis of Randomized Controlled Trials With Novel Hormonal Therapies for Non-Metastatic Castration-Resistant Prostate Cancer: An Update From Mature Overall Survival Data
by: Martina Maggi, et al.
Published: (2021-06-01)

Past, Current, and Future of Immunotherapies for Prostate Cancer
by: Adeline N. Boettcher, et al.
Published: (2019-09-01)

Efficacy and safety of 177Lutetium-prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer patients: First experience in West Asia – A prospective study
by: Ramin Akbarian Aghdam, et al.
Published: (2019-01-01)

Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation
by: Kim van der Zande, et al.
Published: (2021-08-01)

The efficacy of abiraterone acetate in treating Taiwanese chemo-refractory metastatic castration-resistant prostate cancer patients
by: Tony Wu, et al.
Published: (2016-12-01)

Determine of the optimal number of cycles of docetaxel in the treatment of metastatic castration-resistant prostate cancer
by: Yuan-Chi Shen, et al.
Published: (2016-09-01)

Surface-enhanced Raman spectroscopy of serum predicts sensitivity to docetaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer
by: Jianian Hu, et al.
Published: (2021-07-01)

Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives
by: El-Amm J, et al.
Published: (2017-07-01)

Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors
by: Liancheng Fan, et al.
Published: (2018-12-01)

Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study
by: Restelli U, et al.
Published: (2017-12-01)

Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castrate-Resistant Prostate Cancer
by: Kase AM, et al.
Published: (2020-10-01)